ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1767

Poor Body Image in Lupus: Is It Disease Activity, Damage, Sleep, Pain, Fatigue, Stress, Function, Medications, Depression or Fibromyalgia?

Stacy Weinberg1, Nisarg Gandhi2, Meenakshi Jolly3, Winston Sequeira2 and Shilpa Arora2, 1Rush University Medical Center, Chicago, IL, 2Rheumatology, Rush University Medical Center, Chicago, IL, 3Rush, Chicago, IL

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Body image, fibromyalgia, pain and stress, SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with systemic lupus erythematosus (SLE) have poorer body image (BI) than age matched controls. Few studies have been done looking at the effect of disease activity, damage, sleep, stress, pain, fatigue, function, medications, depression and fibromyalgia (FM) in SLE patients. These 10 variables are frequently correlated, and their individual effect on BI is difficult to tease out. To improve BI in SLE, we need to better understand where we need to focus our attention among these 10 variables to guide development of specific interventions. We aimed to evaluate the relative role of disease activity, damage, sleep, stress, pain, fatigue, function, medications, depression and FM on BI in SLE patients.

Methods: 115 SLE patients receiving rheumatology care at two academic medical centers were recruited. Each patient completed the following: Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT), Perceived Stress Scale (PSS), Patient Health Questionnaire (PHQ-9 for depression), Insomnia Severity Index (ISI), pain inventory and LupusPro.  Body image and physical function was measured using the BI (BILS) and Physical health (PH) domains of LupusPRO.  Disease activity and damage were assessed using SELENA-SLEDAI (SS) and SLICC/ACR Damage Index (SDI). Charts were reviewed to evaluate if the patient had been diagnosed with FM by a rheumatologist.  Multivariate regression analyses (including stepwise modelling) were conducted with BI as the dependent variable for (a) all patients, and for patients (b) without and (c) with FM.

Results: 115 SLE patients with mean (SD) age of 40 (14) yrs.  Ninety percent were women, and 15% had concomitant FM. Over 60% were currently on prednisone. Mean (SD) SS and BILS score were 4.8 (4.1) and 74.5 (27.7) respectively.  For all patients, with all 10 variables in the regression analysis, PSS remained the single independent inverse predictor of BI after adjusting for other 9 variables. On stepwise regression, PSS and Pain were predictors of BI (Table 1). Among SLE patients without FM, the SS, PSS, PHQ were independent predictors of poor BI, after adjusting for the other 6 variables.  On stepwise modeling, only PSS, PHQ, and SS were predictors of BI among non-FM SLE patients. When SS was replaced by SS arthritis, rash, alopecia items in this model, PSS, PHQ and active rash were found to be independent predictors. Among SLE patients with FM, none of the 9 variables independently predicted poor BI. On stepwise modelling PH was a predictor of BI in SLE patients with FM.

Conclusion: PSS (and not FM or steroid use) is an important and independent predictor of BI for all SLE patients. Among SLE patients without FM, besides PSS, active disease (rash specially) and depression are also important drivers of poor BI.

All patients (n=94)

(-) FM (n=81)

(+) FM (n=12)

Full model

Stepwise

Full model

Stepwise

Full model

Stepwise

β

95%CI

p

β

95%CI

p

β

95%CI

p

β

95%CI

p

β

95%CI

p

β

95%CI

p

Sleep

-0.11

-1.31-0.49

0.37

0.03

-0.99-1.19

0.85

0.08

-2.15-2.57

0.80

FACIT

-0.03

-0.38-0.28

0.77

0.03

-0.30-0.40

0.78

1.28

-0.01-3.82

0.05

PHQ

-0.12

-0.69-0.22

0.30

-0.42

-3.24- -0.62

0.004

-0.45

-2.92- -1.16

<0.001

0.23

-0.70-1.02

0.59

Pain

-0.11

-0.82-0.35

0.42

-0.34

-1.12- -0.34

<0.001

-0.13

-0.91-0.31

0.34

-0.83

-5.59-2.67

0.34

PSS

-0.27

-3.63- -0.49

0.01

-0.36

-4.16- -1.39

<0.001

-0.22

-3.52- -0.03

0.046

-0.20

-3.23- -0.03

0.046

-0.51

-10.6-4.84

0.32

PH

0.14

-0.12- 0.41

0.27

-0.03

-0.32-0.25

0.82

0.43

-0.97-1.61

0.49

0.75

0.22-0.87

0.003

FM

0.09

-8.26-21.49

0.38

Steroid

-0.05

-14.1-8.24

0.60

0.01

-11.4-12.5

0.93

-0.49

-44.4-0.004

0.05

SS

-0.17

-2.35-0.23

0.11

-0.23

-2.76- -0.16

0.03

-0.26

-2.70- -0.54

0.004

1.10

-2.77-20.5

0.09

SDI

0.11

-1.78-7.44

0.22

0.07

-2.81-6.58

0.43

0.42

-5.18-26.8

0.12


Disclosure: S. Weinberg, None; N. Gandhi, None; M. Jolly, Pfizer Inc, 9; W. Sequeira, None; S. Arora, None.

To cite this abstract in AMA style:

Weinberg S, Gandhi N, Jolly M, Sequeira W, Arora S. Poor Body Image in Lupus: Is It Disease Activity, Damage, Sleep, Pain, Fatigue, Stress, Function, Medications, Depression or Fibromyalgia? [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/poor-body-image-in-lupus-is-it-disease-activity-damage-sleep-pain-fatigue-stress-function-medications-depression-or-fibromyalgia/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/poor-body-image-in-lupus-is-it-disease-activity-damage-sleep-pain-fatigue-stress-function-medications-depression-or-fibromyalgia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology